CMV prophylaxis after renal transplantation with immunoglobulin or CMV-hyperimmunoglobulin--a prospective clinical trial.
Three groups of 40 patients each entered this prospective randomized trial. Patients of group A received 2 ml/kg body weight CMV-Polyglobulin, patients of group B 15 g Intraglobin and patients of group C, serving as controls, received no specific anti-CMV prophylaxis. All patients were given the same sequential immunosuppressive therapy. Patient survival and graft function did not show any significant differences at 2 years follow up. The incidence of fever, CMV infections, dialysis and steroid bolus therapy were lower in group A, but without statistical significance. Patients receiving a graft from a CMV-AK-positive donor were at high risk of developing an infection or reactivation of CMV. A study examining this subgroup seems appropriate.
Stippel
D
D
Department of Surgery, University of Cologne, Cologne, FRG.
Wienand
P
P
Weissenberg
N
N
Baldamus
C
C
Kruppenbacher
U
U
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000009:adverse effects / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D012086:Reoperation; D016019:Survival Analysis; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D000914:Antibodies, Viral; D000961:Antilymphocyte Serum; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D001379:Azathioprine